Cargando…

Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency

Immunosuppressive agents are the standard therapeutic approach for immune thrombocy-topenia (ITP). Their prolonged use may increase the risk of infectious complications, particularly when the patient is already at higher infectious risk. In this setting, the use of drugs with a mechanism of action a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palandri, Francesca, Polverelli, Nicola, Lifrieri, Francesca, Catani, Lucia, Giannini, Maria Benedetta, Baccarani, Michele, Vianelli, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PAGEPress Publications 2012
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401131/ https://www.ncbi.nlm.nih.gov/pubmed/22826792 http://dx.doi.org/10.4081/hr.2012.e10

Ejemplares similares

Circulating Calreticulin Is Increased in Myelofibrosis: Correlation with Interleukin-6 Plasma Levels, Bone Marrow Fibrosis, and Splenomegaly
por: Sollazzo, Daria, et al.
Publicado: (2016)

Romiplostim for the Emergency Management of Severe Immune Thrombocytopenia with Intracerebral Hemorrhage
por: Gellens, Romain, et al.
Publicado: (2018)

Romiplostim for chemotherapy‐induced thrombocytopenia: Efficacy and safety of extended use
por: Wilkins, Cy R., et al.
Publicado: (2022)

The role of romiplostim for pediatric patients with immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2020)

Romiplostim use in pregnant women with immune thrombocytopenia
por: Bussel, James B., et al.
Publicado: (2022)

Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia
por: Chandrakala, S., et al.
Publicado: (2022)

Crucial factors of the inflammatory microenvironment (IL-1β/TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study
por: Sollazzo, Daria, et al.
Publicado: (2016)

The relevance of a low JAK2(V617F) allele burden in clinical practice: a monocentric study
por: Perricone, Margherita, et al.
Publicado: (2017)

Correction to: Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia
por: Chandrakala, S., et al.
Publicado: (2023)

Romiplostim as a treatment for immune thrombocytopenia: a review
por: Chalmers, Sarah, et al.
Publicado: (2015)

Role of romiplostim in splenectomized and nonsplenectomized patients with immune thrombocytopenia
por: Perdomo, Jose
Publicado: (2016)

Risk of Immune Thrombocytopenia Relapse and Onset Related to Sars-Cov-2 Infection and Vaccination
por: Auteri, Giuseppe, et al.
Publicado: (2022)

Immune Thrombocytopenia Onset and Relapse During the COVID-19 Pandemic. A Monocenter Study
por: Auteri, Giuseppe, et al.
Publicado: (2023)

Total remission of severe immune thrombocytopenia after short term treatment with romiplostim
por: Vlachaki, Efthymia, et al.
Publicado: (2011)

Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia
por: Soff, Gerald A., et al.
Publicado: (2019)

Myelofibrosis Associated with Romiplostim Treatment in a Patient with Immune Thrombocytopenia
por: Gonzalez, Maria Fernanda, et al.
Publicado: (2012)

Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland
por: Lee, Dawn, et al.
Publicado: (2013)

Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia
por: Vishnu, Prakash, et al.
Publicado: (2016)

Treatment of 5 dogs with immune-mediated thrombocytopenia using Romiplostim
por: Kohn, Barbara, et al.
Publicado: (2016)

Romiplostim and Eltrombopag in Immune Thrombocytopenia as a Second-Line Treatment
por: Bidika, Erjola, et al.
Publicado: (2020)

Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia
por: Grainger, John D., et al.
Publicado: (2021)

The diagnostic role of Next Generation Sequencing in uncovering isolated splenomegaly: A case report
por: Auteri, Giuseppe, et al.
Publicado: (2021)

Long-Term Use of the Thrombopoietin-Mimetic Romiplostim in Children With Severe Chronic Immune Thrombocytopenia (ITP)
por: Bussel, James B, et al.
Publicado: (2015)

Erratum to: Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland
por: Lee, Dawn, et al.
Publicado: (2013)

Erratum to: treatment of 5 dogs with immune-mediated thrombocytopenia using romiplostim
por: Kohn, Barbara, et al.
Publicado: (2016)

Successful Percutaneous Nephrolithotomy in Patients with Immune-Mediated Thrombocytopenia Treated with Romiplostim
por: McCall, Andrew N., et al.
Publicado: (2016)

Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia
por: Cines, Douglas B., et al.
Publicado: (2017)

Romiplostim for the Treatment of Immune Thrombocytopenia: Spotlight on Patient Acceptability and Ease of Use
por: Gilbert, Megan M, et al.
Publicado: (2020)

Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim
por: Pecci, Alessandro, et al.
Publicado: (2017)

Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives
por: Vianelli, Nicola, et al.
Publicado: (2022)

Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia
por: Janssens, Ann, et al.
Publicado: (2016)

Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim
por: Michel, Marc, et al.
Publicado: (2011)

New synergistic efficacy of combination of romiplostim and steroid in refractory immune thrombocytopenia patients
por: Yoon, Jun Seok, et al.
Publicado: (2018)

Romiplostim-related myelofibrosis in refractory primary immune thrombocytopenia: A Case report
por: Kim, Hyun-Young, et al.
Publicado: (2019)

Immunomodulation in Primary Immune Thrombocytopenia: A Possible Role of the Fc Fragment of Romiplostim?
por: Schifferli, Alexandra, et al.
Publicado: (2019)

Efficacy and quality of life of Romiplostim in adults and children with immune thrombocytopenia: A review
por: He, Xin, et al.
Publicado: (2022)

Safety and efficacy of romiplostim in children and adolescents with Immune thrombocytopenia: A systematic review
por: de Oliveira, Fernanda Lubiana, et al.
Publicado: (2023)

PB2612: UNITED KINGDOM RETROSPECTIVE OBSERVATIONAL STUDY OF ROMIPLOSTIM AND OTHER TREATMENTS IN EARLY IMMUNE THROMBOCYTOPENIA
por: Mcdonald, Vickie, et al.
Publicado: (2023)

Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia
por: Tremblay, Gabriel, et al.
Publicado: (2018)

Chronic immune thrombocytopenia in Denmark, Sweden and Norway: The Nordic Country Patient Registry for Romiplostim
por: Christiansen, Christian Fynbo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_oibi54m879kh9jr5l273hu8lcl